Ra Medical Systems, Inc. RMED
We take great care to ensure that the data presented and summarized in this overview for Ra Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RMED
Top Purchases
Top Sells
About RMED
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
Insider Transactions at RMED
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
9,528
+2.81%
|
$0
$0.6 P/Share
|
|
Jan 22
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
9,528
+2.89%
|
$0
$0.43 P/Share
|
|
Jan 19
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
8,470
+2.65%
|
$0
$0.42 P/Share
|
|
Jan 18
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
8,470
+2.73%
|
$0
$0.41 P/Share
|
|
Jan 16
2024
|
David A Jenkins Executive Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
16,263
+2.73%
|
$0
$0.39 P/Share
|
|
Mar 23
2023
|
James Joseph Caruso |
BUY
Conversion of derivative security
|
Direct |
1,779
+50.0%
|
-
|
|
Mar 23
2023
|
Susanne Meline |
BUY
Conversion of derivative security
|
Indirect |
2,575
+50.0%
|
-
|
|
Mar 23
2023
|
David A Jenkins Executive Chairman and CEO |
BUY
Conversion of derivative security
|
Indirect |
711,967
+50.0%
|
-
|
|
Mar 23
2023
|
David A Jenkins Executive Chairman and CEO |
BUY
Conversion of derivative security
|
Direct |
277,597
+50.0%
|
-
|
|
Nov 20
2022
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-7.2%
|
$168
$2.67 P/Share
|
|
May 20
2022
|
Andrew C. Jackson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,361
-5.91%
|
$0
$0.3 P/Share
|
|
May 20
2022
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,241
-6.36%
|
$0
$0.3 P/Share
|
|
Nov 22
2021
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Open market or private sale
|
Direct |
8,149
-10.88%
|
$16,298
$2.62 P/Share
|
|
Nov 22
2021
|
Andrew C. Jackson CFO |
SELL
Open market or private sale
|
Direct |
2,684
-10.43%
|
$5,368
$2.62 P/Share
|
|
Nov 20
2021
|
Jonathan Will Mc Guire CEO & Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,752
-31.7%
|
-
|
|
Nov 20
2021
|
Andrew C. Jackson CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,759
-31.37%
|
-
|
|
Jun 04
2021
|
Martin J Colombatto |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+11.96%
|
-
|
|
Jun 04
2021
|
William R Enquist Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+17.57%
|
-
|
|
Jun 04
2021
|
Richard Mejia Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.42%
|
-
|
|
Jun 04
2021
|
Joan Stafslien Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+32.23%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 52.3K shares |
|---|